A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2027

Conditions

Relapse Multiple MyelomaRefractory Multiple Myeloma

Interventions

DRUG

BCMA Targeted CAR T-cells

Each subject receive BCMA Targeted CAR T-cells by intravenous infusion

Trial Locations (1)

The First Affiliated Hospital, Medical College, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER